118 results about "Inosine" patented technology

The present disclosure, in some aspects, relates to antisense oligonucleotides (ASO) for use in the prevention or treatment of a disease or a condition associated with low- density lipoprotein (LDL) in a subject. In some embodiments, the ASO effects site-directed adenosine-to-inosine (A-to-l) editing of a target adenosine in a target RNA sequence derived from a sequence of an endogenous low-density lipoprotein receptor (LDLR) gene such that: a) the modified LDLR protein has: (i) reduced binding to the inducible degrader of the LDLR protein (IDOL); (ii) increased stability; (iii) improved resistance to IDOL-mediated degradation; (iv) increased LDLR protein expression; and / or (v) increased activity or function to take up LDL; and / or b) editing of the 3'-untranslated region (UTR) of the target RNA leads to an increase in LDLR protein expression and / or stability.

The invention relates to application of plant lactobacillus FBL002 in degradation of purine nucleoside, and belongs to the technical field of microorganisms. The plant lactobacillus FBL002 provided by the invention is preserved in Guangdong Microbial Culture Collection Center on March 13, 2025, and the preservation number is GDMCC No.66015. The strain is separated from healthy infant intestinal flora, and can effectively degrade various purine nucleosides including inosine, guanosine, adenosine, guanine and adenine, so that the plant lactobacillus FBL002 is used for developing products for degrading purine nucleosides. In addition, the strain is also suitable for preparing oral hyperuricemia treatment medicines, and the contents of uric acid, xanthine oxidase and adenosine deaminase in serum can be remarkably reduced. The invention provides a safe and efficient method for managing purine metabolism abnormality related diseases by utilizing the biodegradation activity of the plant lactobacillus FBL002, and is particularly suitable for preventing and treating hyperuricemia.

The invention relates to the technical field of molecular markers and animal genetic breeding, in particular to an SNP marker influencing the content of porcine inosine and application of the SNP marker. The 10 SNP molecular markers closely related to the porcine inosine content are researched and determined on the basis of American-series purebred landrace, American-series purebred large white pigs and American-series purebred duroc, the dominant allele frequency can be increased generation by generation by optimizing the dominant allele of the SNP, the inosine content can be reduced, and the molecular markers can be used for identifying the porcine inosine content. The pig genetic improvement progress is accelerated, so that the economic benefit of breeding pig breeding is effectively improved.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus mucus BU360 with the function of improving uric acid, blood fat and blood glucose metabolism and application of the lactobacillus mucus BU360. The preservation number of the lactobacillus fermentum BU360 provided by the invention is CGMCC (China General Microbiological Culture Collection Center) No.33032. The lactobacillus fermentum BU360 provided by the invention has the advantages that the preservation number is CGMCC No.33032; the lactobacillus mucus BU360 can efficiently degrade guanosine and inosine which are precursor substances for synthesizing uric acid and directly degrade the uric acid, thalli, cell contents and metabolites of the lactobacillus mucus BU360 can inhibit the activity of xanthine oxidase and relieve HUA, and the lactobacillus mucus BU360 can directly degrade cholesterol and inhibit the activity of alpha-glucosidase and alpha-amylase, so that the lactobacillus mucus BU360 can be used for preparing the uric acid. The polypeptide has potential capability of improving blood fat and blood glucose metabolism abnormality, and assists in treatment of HUA; besides, the strain has relatively strong acid-resistant and cholate-resistant characteristics, can smoothly reach the intestinal tract of a human body, has relatively good safety on sensitivity of various antibiotics, and lays a foundation for development of related probiotic products. The lactobacillus mucus BU360 has a wide application prospect in the aspect of preparing products for relieving HUA, improving blood fat and blood glucose metabolism and the like.

The invention discloses a lactobacillus buchneri complex microbial inoculant and application thereof, and belongs to the technical field of microorganisms. In order to solve the problem of poor direct degradation effect of lactic acid bacteria on uric acid in the prior art, the invention provides a complex microbial inoculant containing lactobacillus buchneri NEFU-1 and NEFU-2, and the complex microbial inoculant has the functions of degrading uric acid, relieving hyperuricemia, degrading inosine and / or guanosine, improving intestinal flora composition and reducing inflammatory factors; the lactobacillus plantarum has important significance on preventing, improving and treating gout and hyperuricemia diseases, has high application value and can be applied to preparation of fermented yoghurt.

The present invention relates to antisense oligonucleotides (AONs) that can mediate RNA editing by binding to a target RNA nucleic acid molecule, preferably an RNA transcript molecule, in a cell and recruiting an endogenous deaminating enzyme in the cell to deaminate a target adenosine in the target RNA molecule to an inosine. The target RNA molecule is a transcript molecule form the SLC10A1 gene that encodes the Na+ / Taurocholate Co-transporting Polypeptide (NTCP), and the target adenosine is the adenosine in the GAC codon coding for aspartic acid (D) at position 24 of the NTCP protein. The deamination of the adenosine changes the amino acid to a glycine (G). The RNA editing of the adenosine will result in a loss-of-function of the NTCP protein, which will result in lowered uptake of bile acids from the portal circulation into the liver, thereby lowering the risk of suffering from disorders related to bile accumulation in the liver.

The invention discloses a saccharomycetes lysate, a preparation method and application, and the main components of the saccharomycetes lysate comprise the following components accounting for the relative content of the saccharomycetes lysate: 93-98% of nucleoside, nucleotide and derivatives thereof; and 0.2 to 6% of amino acid; wherein the nucleoside, the nucleotide and the derivatives of the nucleoside and the nucleotide comprise one or more of adenosine, succinyladenosine, adenosine-3 '-phosphoric acid, inosine and S-adenosine homocysteine. Effect evaluation is carried out on the saccharomycetes lysate, and verification shows that the saccharomycetes lysate has the effects of whitening, repairing skin injury, preventing light and aging, resisting pollution and oxidation, resisting inflammation and relieving, protecting hair and preventing hair loss, replenishing water and preserving moisture, and enhancing skin vitality or removing dark circles.

The invention relates to lactobacillus reuteri SAU-R-8 which is derived from Tibet naturally-fermented sour yak milk and is used for producing exopolysaccharides and application of the lactobacillus reuteri SAU-R-8 in reducing uric acid, and belongs to the technical field of microorganisms. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30373, and the preservation date is April 19, 2024. The lactobacillus reuteri SAU-R-8 provided by the invention is screened from yak yogurt naturally fermented from herdsmen in the Sankarst region of Tibet, the yield of exopolysaccharides in an MRS culture medium reaches 318.57 mg / L, nucleoside substances such as inosine and guanosine can be efficiently degraded, purine substances such as guanine can be efficiently absorbed, the activity of xanthine oxidase can be inhibited, and the lactobacillus reuteri SAU-R-8 can be used for preparing the yak yogurt. The method can be further applied to product development for relieving or treating hyperuricemia.

The present invention addresses the problem of providing a medicine and a food composition for improving motor function. The present invention relates to a motor function improver comprising a combination of (a) one or more components selected from febuxostat and topiroxostat and (b) inosine.

The present invention discloses an application of an IMPDH2 inhibitor in preventing or treating inflammation. The limonoid compound provided by the present invention can bind to and degrade human inosine-5'-monophosphate dehydrogenase 2 (IMPDH2), inhibit the synthesis of intracellular guanine, inhibit the activation of the NF-κB signaling pathway, and can be used as an IMPDH2 inhibitor; the IMPDH2 inhibitor also has a good preventive or therapeutic effect on inflammation. Compared with existing IMPDH2 inhibitors, the limonoid compound provided by the present invention can degrade the IMPDH2 enzyme, has better inhibitory activity, and has stronger activity in inhibiting inflammatory factors.

The invention belongs to the technical field of liquid phase detection, and particularly relates to a quality control and detection method for lumbricus soaked with liquorice. According to the method, methanol water is used as a mobile phase, the content of hypoxanthine and inosine in the lumbricus glycyrrhiza is detected by high performance liquid chromatography, and the method has important significance on quality control of a lumbricus glycyrrhiza product. The detection method disclosed by the invention is good in system applicability, precision, reproducibility, recovery rate and stability, and meets the requirements of Chinese Pharmacopoeia, Chinese Pharmacopoeia, appendix of Chinese Pharmacopoeia, Chinese appendix of Chinese Pharmacopoeia, Chinese Pharmacopoeia, Chinese

The invention belongs to the field of in-vitro diagnostic reagents, and particularly relates to application of a reagent for detecting biomarkers in serum in preparation of a cerebral arterial thrombosis diagnostic kit. The invention determines that the concentrations of lactic acid, isoleucine, fumaric acid, ketoglutaric acid, hypoxanthine, tyrosine, histidine and inosine in serum of a cerebral arterial thrombosis (IS) patient are significantly related to major atherosclerosis (LAA) and minor artery occlusion (SAO), so that the concentrations of the biomarkers can be used as a basis for diagnosing IS and distinguishing LAA and SAO.

The invention relates to the technical field of bioengineering, in particular to an AimA mutant as well as a construction method and application thereof. It is found for the first time that the activity of glutamic acid / serine transporter is weakened, and the nucleoside production capacity of microorganisms can be improved. Based on this, the present invention provides a modified microorganism in which the glutamic acid / serine transporter activity is reduced or lost as compared to an unmodified microorganism, and the nucleoside production capacity of the modified microorganism is enhanced as compared to the unmodified microorganism, and more specifically, the modified microorganism has a reduced or lost glutamic acid / serine transporter activity as compared to the unmodified microorganism. The modified bacillus subtilis or bacillus amyloliquefaciens provided by the invention can generate guanine nucleoside or hypoxanthine nucleoside with high efficiency and high speed.

The present invention relates to antisense oligonucleotides (AONs) that can mediate RNA editing by binding to a target RNA nucleic acid molecule, preferably an RNA transcript molecule, in a cell and recruiting an endogenous deaminating enzyme in the cell to deaminate one or more target adenosine nucleotides in the target RNA molecule to an inosine. The target RNA molecule is a transcript molecule from the human galactokinase (GALK1) gene that preferably encodes a wildtype GALK1 protein. The RNA editing of the target adenosine, changing an aspartic acid (D) residue to a glycine (G) residue at position 186 in the protein, results in a GALK1 protein with a loss-of-function in its ability to phosphorylate galactose, thereby reducing the amount of galactose-1-phosphate (Gal-1-P), which is one of the major accumulating metabolites in classic galactosemia caused by a galactose-1-phosphate uridylyltransferase (GALT) deficiency, providing a potential treatment for classic galactosemia.

Provided herein is a eukaryotic cell expressing an exogenously introduced inosine 5'-monophosphate dehydrogenase (IMPDH) that is resistant to a purine biosynthesis inhibitor, uses thereof for producing therapeutic agents and treating a disease or disorder, as well as pharmaceutical compositions and methods of making thereof.

Provided herein is an antisense oligonucleotide (ASO) for use in the prevention or treatment of a disease or a condition associated with ApoB in a subject, wherein the ASO effects site- directed adenosine-to-inosine (A-to-l) editing of a target adenosine in a target RNA sequence derived from a sequence of an endogenous ApoB gene.

The present invention provides a therapeutic drug for frailty or muscular dystrophy, and particularly for sarcopenia, and a medicinal drug for improving motor function. The present invention provides a motor function improver that contains a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof and additionally contains an ATP precursor substance or is used in combination with an ATP precursor substance. The ATP precursor substance is preferably inosine, inosinic acid, or hypoxanthine. This motor function improver is preferably used as a medicinal drug and is used as a therapy or preventive for frailty and sarcopenia and as a therapy or preventive for muscle wasting and muscle loss.

An agent is for inhibiting glucose uptake into red blood cells and a blood collection tube suppresses glucose concentration decrease. The agent for inhibiting glucose uptake into red blood cells includes inosine as an active ingredient. The inhibition agent can be used for suppressing a decrease in glucose concentration of whole blood collected in a blood collection tube. The blood collection tube includes inosine in an internal space. The blood collection tube can be used to measure glucose concentration in blood. The blood collection tube can further include a glycolysis inhibitor.

This disclosure provides methods for treating neurodegenerative diseases and restoring neuronal synaptic function by administering adenosine-to-inosine editing modifiers.

The invention discloses a preparation method of 1, 7-dimethylxanthine, which adopts inosine as a starting material, and the developed catalyst porphyrin-loaded xanthine oxidase and nano metal oxide can be recycled for multiple times, thereby greatly lowering the production cost. More importantly, safety accidents occur frequently in recent years, a route design strategy for avoiding dangerous reactions becomes more and more important, and the route avoids the use of a diazotization dangerous process, so that the production safety risk is greatly reduced.

The invention relates to a biomarker for evaluating progression and prognosis of paraquat poisoning and application of the biomarker. The biomarker is a urine metabolite Inosine. Urine non-target metabonomics analysis shows that the level of the Inosine is low in urine of a patient suffering from early paraquat poisoning, is gradually reduced along with aggravation of the illness state and is remarkably increased in follow-up visit of five years; the prediction efficiency is judged according to the area (AUC) below the working characteristic (ROC) curve of a subject, the Anosine has good efficiency (AUC = 0.806) in judging the progression of paraquat poisoning, has good efficiency (AUC = 0.816) in judging the prognosis aspect in 1-4 days at the early stage of poisoning, and has excellent efficiency (AUC = 0.961) in judging the prognosis aspect in 7-14 days at the progression stage of poisoning. Moreover, the efficiency of the Inosine in predicting the progress and prognosis of paraquat poisoning is better than that of blood routine indexes (such as the number of leukocytes, the percentage of neutrophils and the percentage of lymphocytes) reported in the literature. In conclusion, as the biomarker for prognosis and prognosis of paraquat poisoning, the Inosine shows a good clinical application prospect.

The invention discloses a multiplex PCR (Polymerase Chain Reaction) detection kit based on microsatellite instability sites of endometrial cancer. The kit comprises a primer group and a premixed solution, the primer group comprises a primer for detecting at least one of a site BAT-25, a site BAT-26, a site NR-24, a site MONO-27, a site CAT-25, a site BAT-59 and a site BAT-60, and the primer contains two inosine (I) and a stem-loop structure (SEQ ID NO.22) so as to simultaneously detect different states of MSI Del and Ins; according to the kit, when MSI detection is used for carrying out microsatellite instability judgment on endometrial cancer on seven combination sites and corresponding target coverage sections, capillary electrophoresis detection and common PCR (Polymerase Chain Reaction) and digital PCR detection can be carried out at the same time, so that the gradient among detection result numerical values is more refined, and the MSI state is accurately defined as high, low or stable; the kit has the advantages that reagent material cost is saved, detection period is shortened, detection in an extreme period is achieved, clinical multi-sample detection requirements are met, and the kit has the advantages of high sensitivity, specificity and repeatability.

The present invention relates to methods and compositions for disrupting interaction of an NRF2 protein and a KEAP1 protein. The methods include contacting at least one polynucleotide selected from the group consisting of a polynucleotide encoding the NRF2 protein and a polynucleotide encoding the KEAP1 protein with a guide oligonucleotide that effects one or more (e.g., at least two) adenosine deaminase acting on RNA (ADAR)-mediated adenosine to inosine alterations in said at least one polynucleotide, wherein the adenosine to inosine alterations generate a mutant amino acid, thereby disrupting interaction of the NRF2 protein and the KEAP1 protein. The invention also relates to methods of treating a KEAP1-NRF2 pathway related disease in a subject in need thereof, the method comprising contacting, within the subject, at least one polynucleotide selected from the group consisting of a polynucleotide encoding an NRF2 protein and a polynucleotide encoding a KEAP1 protein with a guide oligonucleotide that effects an adenosine deaminase acting on RNA (ADAR)-mediated adenosine to inosine alteration in said at least one polynucleotide, wherein the adenosine to inosine alteration generates a mutant amino acid, thereby disrupting interaction of the NRF2 protein and the KEAP1 protein and treating the disease in the subject; and compositions thereof.

This invention discloses *Pediococcus lactis* TC-4, which simultaneously degrades nucleosides, purines, and uric acid, and its applications. *Pediococcus lactis* ( Pediococcus acidilactici This invention relates to *Pediococcus lactis* TC-4, with accession number GDMCC No: 67936. *Pediococcus lactis* TC-4 of this invention can efficiently degrade three nucleosides (guanosine, adenosine, and inosine), three purines (guanine, xanthine, and hypoxanthine), and uric acid in vitro. *Pediococcus lactis* TC-4 of this invention can effectively reduce serum uric acid levels in broiler chickens, alleviating and treating hyperuricemia. Compared with traditional chemical drugs for treating hyperuricemia and / or gout, this invention has no toxic side effects on the ecological environment, no residue risk, and is green and safe. This invention has been confirmed at multiple levels, including genetic and animal studies, to have no potential harm to humans, demonstrating its advantages of safety and high efficiency.

Provided are methods of manufacturing cells. The methods comprise expanding cells in the presence of inosine, and harvesting the cells after expansion. In certain embodiments, the cells are genetically modified. For example, the cells may be genetically modified to express an engineered receptor, non-limiting examples of which are chimeric antigen receptors (CARs), engineered T cell receptors (TCRs), and the like. According to some embodiments, the cells are immune cells, e.g., T cells or natural killer cells. Also provided are populations of cells manufactured according to the methods of the present disclosure. Also provided are methods comprising administering an effective amount of a population of cells manufactured according to the methods of the present disclosure to a subject in need thereof. In certain embodiments, the subject has cancer, and the cells express an engineered receptor that binds to a tumor antigen on the surface of cells of the cancer.

This invention relates to the field of probiotics technology, specifically to a Bifidobacterium adolescentis BN18 and its postbiotics for lowering uric acid and improving gout symptoms, and their applications. The Bifidobacterium adolescentis BN18 can promote the degradation of inosine and guanosine, thereby reducing uric acid levels in the blood. The postbiotics for Bifidobacterium adolescentis BN18 are made from carefully selected raw materials such as carrots, winter melon, blueberries, apples, lemons, and fructooligosaccharides as the core components of the composition. Through deep fermentation with BN18, the resulting postbiotics not only reduce the activity of xanthine oxidase and lower uric acid levels in the blood, thus promoting uric acid reduction, but also significantly enhance their antioxidant properties, reducing inflammatory responses, lowering inflammation levels, alleviating joint pain, and improving gout symptoms.

The invention provides a method for simultaneously determining various flavor nucleotides in a livestock and poultry meat product and application, and the method comprises the following steps: freeze-drying the livestock and poultry meat product, and then preparing the freeze-dried livestock and poultry meat product into a test solution; measuring the contents of CMP (cytidylic acid), ATP (adenosine triphosphate), GMP (guanine monophosphate), IMP (inosinic acid), ADP (adenosine diphosphate), Hy (hypoxanthine), AMP (adenosine monophosphate) and IN (inosine) in the test solution by adopting HPLC (high performance liquid chromatography); in HPLC, a mobile phase A is a phosphate buffer solution with the volume concentration of 95%, a mobile phase B is methanol with the volume concentration of 5%, gradient elution is carried out, and the gradient elution condition is 0-11 min, 99% phosphate buffer solution and 1% methanol; when 12 min, 80% phosphate buffer solution and 20% methanol are added, and the conditions are maintained for 6-7 min; the phosphate buffer solution is heated to 99% within 2 minutes, and then the temperature is kept for 8-10 minutes.

The present application relates to the field of bioengineering, and particularly relates to a protein mutant capable of improving the nucleoside yield of a strain and application thereof. The present application performs point mutation on adenine deaminase and pyrimidine nucleotide transport protein, which can effectively accumulate the inosine, adenosine and other nucleoside related products produced by the strain, does not affect the growth of the bacterial body, has wider practicality, and is conducive to reducing the cost of industrial production of nucleosides.

Provided is an immunogenic composition for use in raising immunity against the agent of Lyme disease. The composition is based on variants of CspZ and comprises a polypeptide of SEQ ID NO: 1, except that (a) the amino acid whose position corresponds to amino acid 188 of SEQ ID NO: 1 is any amino acid other than tyrosine; and the amino acid whose position corresponds to amino acid 192 of SEQ ID NO: 1 is any amino acid other than tyrosine; and (b) one or both of the amino acids acid whose position corresponds to amino acid 164 of SEQ ID NO: 1 may be an amino acid other than inosine and an amino acid whose position corresponds to amino acid 168 of SEQ ID NO: 1 may be an amino acid other than cysteine. Also provided is a polynucleotide encoding any of the foregoing polypeptides and a method of vaccinating against Lyme disease comprising administering the polypeptide or RNA encoding the polypeptide to a subject.

This disclosure relates to improved methods of identifying A-to-I RNA edits in a sample. In certain embodiments, this disclosure relates to methods of purifying RNA containing an inosine base comprising the steps of: exposing an RNA sample to endonuclease V or fusion thereof and calcium ions in the absence of magnesium ions providing an RNA and endonuclease V binding complex. In certain embodiments, the methods further comprise purifying the RNA and endonuclease V binding complex from unbound RNA in the sample; separating the RNA from endonuclease V providing separated RNA; sequencing the separated RNA; and identifying positions in the RNA sequences wherein A-to-I edits occur. In certain embodiments, the RNA is derived from a cell.